Back to Search Start Over

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.

Authors :
Miller, William
Miller, William
Hoffman, Irving
Hanscom, Brett
Ha, Tran
Dumchev, Kostyantyn
Djoerban, Zubairi
Rose, Scott
Latkin, Carl
Metzger, David
Lancaster, Kathryn
Go, Vivian
Dvoriak, Sergii
Mollan, Katie
Reifeis, Sarah
Piwowar-Manning, Estelle
Richardson, Paul
Hudgens, Michael
Hamilton, Erica
Sugarman, Jeremy
Eshleman, Susan
Susami, Hepa
Chu, Viet
Djauzi, Samsuridjal
Kiriazova, Tetiana
Bui, Duong
Burns, David
Strathdee, Steffanie
Miller, William
Miller, William
Hoffman, Irving
Hanscom, Brett
Ha, Tran
Dumchev, Kostyantyn
Djoerban, Zubairi
Rose, Scott
Latkin, Carl
Metzger, David
Lancaster, Kathryn
Go, Vivian
Dvoriak, Sergii
Mollan, Katie
Reifeis, Sarah
Piwowar-Manning, Estelle
Richardson, Paul
Hudgens, Michael
Hamilton, Erica
Sugarman, Jeremy
Eshleman, Susan
Susami, Hepa
Chu, Viet
Djauzi, Samsuridjal
Kiriazova, Tetiana
Bui, Duong
Burns, David
Strathdee, Steffanie
Source :
The Lancet; vol 392, iss 10149
Publication Year :
2018

Abstract

BACKGROUND: People who inject drugs (PWID) have a high incidence of HIV, little access to antiretroviral therapy (ART) and medication-assisted treatment (MAT), and high mortality. We aimed to assess the feasibility of a future controlled trial based on the incidence of HIV, enrolment, retention, and uptake of the intervention, and the efficacy of an integrated and flexible intervention on ART use, viral suppression, and MAT use. METHODS: This randomised, controlled vanguard study was run in Kyiv, Ukraine (one community site), Thai Nguyen, Vietnam (two district health centre sites), and Jakarta, Indonesia (one hospital site). PWID who were HIV infected (index participants) and non-infected injection partners were recruited as PWID network units and were eligible for screening if they were aged 18-45 years (updated to 18-60 years 8 months into study), and active injection drug users. Further eligibility criteria for index participants included a viral load of 1000 copies per mL or higher, willingness and ability to recruit at least one injection partner who would be willing to participate. Index participants were randomly assigned via a computer generated sequence accessed through a secure web portal (3:1) to standard of care or intervention, stratified by site. Masking of assignment was not possible due to the nature of intervention. The intervention comprised systems navigation, psychosocial counselling, and ART at any CD4 count. Local ART and MAT services were used. Participants were followed up for 12-24 months. The primary objective was to assess the feasibility of a future randomised controlled trial. To achieve this aim we looked at the following endpoints: HIV incidence among injection partners in the standard of care group, and enrolment and retention of HIV-infected PWID and their injection partners and the uptake of the integrated intervention. The study was also designed to assess the feasibility, barriers, and uptake of the integrated intervention. Endpoi

Details

Database :
OAIster
Journal :
The Lancet; vol 392, iss 10149
Notes :
application/pdf, The Lancet vol 392, iss 10149
Publication Type :
Electronic Resource
Accession number :
edsoai.on1410328688
Document Type :
Electronic Resource